摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-溴-1H-吡唑并[3,4-d]嘧啶-4,6-二胺 | 144750-82-3

中文名称
3-溴-1H-吡唑并[3,4-d]嘧啶-4,6-二胺
中文别名
1H-吡唑并[3,4-d]嘧啶-4,6-二胺,3-溴-
英文名称
2,4-Diamino-5-bromo-7H-pyrazolo<3,4-d>pyrimidine
英文别名
3-bromo-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine;3-bromo-2H-pyrazolo[3,4-d]pyrimidine-4,6-diamine
3-溴-1H-吡唑并[3,4-d]嘧啶-4,6-二胺化学式
CAS
144750-82-3
化学式
C5H5BrN6
mdl
——
分子量
229.039
InChiKey
FVOVQYNWRQMJNK-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    341.4±52.0 °C(Predicted)
  • 密度:
    2.82±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.5
  • 重原子数:
    12
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    107
  • 氢给体数:
    3
  • 氢受体数:
    5

SDS

SDS:8b9a928431f3d2ee2da4a6d721dd31a7
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    3-溴-1H-吡唑并[3,4-d]嘧啶-4,6-二胺三氟化硼乙醚 吡啶甲醇sodium methylatesilver nitrate 作用下, 以 四氢呋喃甲醇硝基甲烷 为溶剂, 生成 N-[1-[5-[bis-(4-methoxy-phenyl)-phenyl-methoxymethyl]-3-(tert-butyl-dimethyl-silanyloxy)-4-hydroxy-tetrahydro-furan-2-yl]-3-bromo-4-(dibutylamino-methyleneamino)-1H-pyrazolo[3,4-d]pyrimidin-6-yl]-formamide
    参考文献:
    名称:
    7-SUBSTITUTED 8-AZA-7-DEAZAPURINES AND 2,8-DIAZA-7-DEAZA-PURINES: SYNTHESIS OF NUCLEOSIDES AND OLIGONUCLEOTIDES
    摘要:
    7-Substituted 8-aza-7-deazaadenosines la-e were synthesized by Sonogashira cross coupling from the corresponding 7-iodo nucleoside in 36- 79% yields. Starting from 7-bromo (or 7-iodo)-8-aza- 7-deazaadenine, 2a,b were obtained by acid-catalyzed glycosylation followed by deprotection in 53 and 35% yields, respectively. Compounds 2b was applied to cross coupling reaction to give 2c-d in 34-95% yield. Compounds 2a and 4b were further transformed to the phosphoramidites 5 and 6b in 9 and 49% overall yields, which were incorporated into oligonucleotides.
    DOI:
    10.1081/ncn-200059218
  • 作为产物:
    描述:
    1H-吡唑并[3,4-D]嘧啶-4,6-二胺 作用下, 以 为溶剂, 反应 1.0h, 以62%的产率得到3-溴-1H-吡唑并[3,4-d]嘧啶-4,6-二胺
    参考文献:
    名称:
    与2-氨基腺苷和异鸟苷有关的吡唑并[3,4-d]嘧啶核糖核苷:合成,脱氨基和互变异构。
    摘要:
    描述了与2-氨基腺苷和异鸟苷相关的8-氮杂-7-脱氮嘌呤(吡唑并[3,4-d]嘧啶)核糖核苷的合成和性质。在BF(3)存在下,将1-氮-乙酰基2,3,5-三-O-苯甲酰基-β-D-呋喃呋喃糖与8-氮杂7-脱氮嘌呤-2,6-二胺5糖基化。 )x Et(2)O作为催化剂,得到N(8)异构体14(73%)和痕量的N(9)异构体13a(4.8%)。在相同的反应条件下,7-卤代8-氮杂-7-脱氮嘌呤-2,6-二胺6-8提供了热力学上更稳定的N(9)核苷13b-d作为唯一产物(53-70%)。因此,位置7的卤素将糖基化作用从N(8)转移到N(9)。通过2-氨基的重氮化将8-氮杂-7-脱氮嘌呤-4,6-二胺核糖核苷1a-d转化为异鸟苷衍生物3a-d。尽管化合物1a b。在7位(酶结合位点)不含氮,它们被腺苷脱氨酶脱氨;但是,它们的脱氨速度比相关嘌呤的速度要慢得多。pK(a)值表明,将7个非功能化核苷1a(pK(a)5
    DOI:
    10.1039/b708736e
点击查看最新优质反应信息

文献信息

  • [EN] PYRROLOTRIAZINONE DERIVATIVES AS PI3K INHIBITORS<br/>[FR] DÉRIVÉS DE PYRROLOTRIAZINONE EN TANT QU'INHIBITEURS DES PI3K
    申请人:ALMIRALL SA
    公开号:WO2014060431A1
    公开(公告)日:2014-04-24
    New pyrrolotriazinone derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Phosphoinositide 3-Kinases (PI3Ks).
    披露了具有公式(I)化学结构的新型吡咯三嗪酮衍生物;以及它们的制备方法,包含它们的药物组合物以及它们作为磷脂酰肌醇3-激酶(PI3Ks)抑制剂在治疗中的用途。
  • Synthesis of pyrazolo 3,4-pyrimidine analogues of the potent agent N-4-2-2-amino-4 3-oxo-7-pyrrolo 2,3-pyrimidin-5-yl ethylbenzoyl-L-glutamic acid (LY231514)
    作者:Edward C. Taylor、Hemantkumar H. Patel
    DOI:10.1016/s0040-4020(01)80479-8
    日期:1992.1
    Several pyrazolo[3,4-d]pyrimidine analogues of the potent antitumor agent N-4-12-(2-amino-4(3H)-oxo-7H-pyrrolo [2,3-d]pyrimidin-5-yl)ethyl]benzoyl}-L-glutamic acid (LY231514, 5) have been prepared. A principal synthetic step proved to be a palladium-catalyzed C-C coupling of the 5-halo-substituted pyrazolo[3,4-d]pyrimidines 12-15 with dimethyl 4-ethynylbenzoyl-L-glutamate (16). An additional pyrazolo[3,4-d]pyrimidine analogue of 5 possessing an isofolic acid bridge unit (-NHCH2-) was prepared by reductive alkylation of diethyl 4-formylbenzoyl-L-glutamate (31) with 2-methyl-5-amino-4(3H)-oxo-7H-pyrazolo[3,4-d]pyrimidine (30). Only compound 26 proved to have in vitro cell growth inhibitory activity.
  • 7-SUBSTITUTED 8-AZA-7-DEAZAPURINES AND 2,8-DIAZA-7-DEAZA-PURINES: SYNTHESIS OF NUCLEOSIDES AND OLIGONUCLEOTIDES
    作者:Wenqing Lin、Kuiying Xu、Frank Seela
    DOI:10.1081/ncn-200059218
    日期:2005.4.1
    7-Substituted 8-aza-7-deazaadenosines la-e were synthesized by Sonogashira cross coupling from the corresponding 7-iodo nucleoside in 36- 79% yields. Starting from 7-bromo (or 7-iodo)-8-aza- 7-deazaadenine, 2a,b were obtained by acid-catalyzed glycosylation followed by deprotection in 53 and 35% yields, respectively. Compounds 2b was applied to cross coupling reaction to give 2c-d in 34-95% yield. Compounds 2a and 4b were further transformed to the phosphoramidites 5 and 6b in 9 and 49% overall yields, which were incorporated into oligonucleotides.
  • Pyrazolo[3,4-d]pyrimidine ribonucleosides related to 2-aminoadenosine and isoguanosine: synthesis, deamination and tautomerism
    作者:Frank Seela、Kuiying Xu
    DOI:10.1039/b708736e
    日期:——
    than that of the related purines. The pK(a) values indicate that the 7-non-functionalized nucleosides 1a (pK(a) 5.8) and 15 (pK(a) 6.4) are possibly protonated in neutral conditions when incorporated into RNA. The nucleosides 3a-d exist predominantly in the keto (lactam) form with K(TAUT) (keto/enol) values of 400-1200 compared to 10(3)-10(4) for pyrrolo[2,3-d]pyrimidine isoguanosine derivatives 4a-c
    描述了与2-氨基腺苷和异鸟苷相关的8-氮杂-7-脱氮嘌呤(吡唑并[3,4-d]嘧啶)核糖核苷的合成和性质。在BF(3)存在下,将1-氮-乙酰基2,3,5-三-O-苯甲酰基-β-D-呋喃呋喃糖与8-氮杂7-脱氮嘌呤-2,6-二胺5糖基化。 )x Et(2)O作为催化剂,得到N(8)异构体14(73%)和痕量的N(9)异构体13a(4.8%)。在相同的反应条件下,7-卤代8-氮杂-7-脱氮嘌呤-2,6-二胺6-8提供了热力学上更稳定的N(9)核苷13b-d作为唯一产物(53-70%)。因此,位置7的卤素将糖基化作用从N(8)转移到N(9)。通过2-氨基的重氮化将8-氮杂-7-脱氮嘌呤-4,6-二胺核糖核苷1a-d转化为异鸟苷衍生物3a-d。尽管化合物1a b。在7位(酶结合位点)不含氮,它们被腺苷脱氨酶脱氨;但是,它们的脱氨速度比相关嘌呤的速度要慢得多。pK(a)值表明,将7个非功能化核苷1a(pK(a)5
查看更多

同类化合物

阿拉格列汀 间型霉素环-3',5'-单磷酸酯 西地那非杂质 苯,[(1-甲基环戊基)硫代]- 苄基-(6-氯-1-甲基-1H-吡唑并[3,4-d]嘧啶-4-基)-胺 甲基-(6-甲基磺酰基-1(2)H-吡唑并[3,4-d]嘧啶-4-基)-胺 环己基-(1-甲基-1H-吡唑并[3,4-d]嘧啶-4-基)-胺 氮杂环庚-1-基-[7-氯-4-噻吩-2-基-2-(三氟甲基)-1,5,9-三氮杂双环[4.3.0]壬-2,4,6,8-四烯-8-基]甲酮 异丙基 4-(1-甲基-7-氧代-3-丙基-6,7-二氢-1H-吡唑并[4,3-d]嘧啶-5-基)噻吩-2-基磺酰基氨基甲酸酯 吡啶-2-基-[7-吡啶-4-基-吡唑[1,5-a]嘧啶-3-基]甲酮 吡唑并[2,3-a]嘧啶 吡唑并[1,5-a]嘧啶-7-胺 吡唑并[1,5-a]嘧啶-7(1h)-酮 吡唑并[1,5-a]嘧啶-6-醇 吡唑并[1,5-a]嘧啶-6-羧酸乙酯 吡唑并[1,5-a]嘧啶-6-羧酸 吡唑并[1,5-a]嘧啶-5-羧酸 吡唑并[1,5-a]嘧啶-3-胺盐酸盐(1:1) 吡唑并[1,5-a]嘧啶-3-胺;三氟乙酸 吡唑并[1,5-a]嘧啶-3-羰酰氯 吡唑并[1,5-a]嘧啶-3-羧酸乙酯 吡唑并[1,5-a]嘧啶-3-羧酸 吡唑并[1,5-a]嘧啶-3-磺酰胺 吡唑并[1,5-a]嘧啶-3-甲酰胺 吡唑并[1,5-a]嘧啶-3-甲腈 吡唑并[1,5-a]嘧啶-2-羧酸乙酯 吡唑并[1,5-a]嘧啶-2-羧酸 吡唑并[1,5-a]嘧啶,2-甲基-6-(1-甲基乙基)- 吡唑并[1,5-a]嘧啶,2-溴-5,7-二甲基- 吡唑并[1,5-A]嘧啶-5-胺 吡唑并[1,5-A]嘧啶-5(4H)-酮 吡唑并[1,5-A]嘧啶-3-甲醛 吡唑[1,5-A]嘧啶-5-羧酸甲酯 吡唑[1,5-A]嘧啶-5,7(4H,6H)-二酮 双氯地那非 别嘌醇 别嘌呤醇D2 二硫代乙基碳萘甲醚 二硫代-脱甲基-昔多芬 乙基7-甲基吡唑并[1,5-a]嘧啶-6-羧酸酯 [1,2]恶唑并[4,3-e]吡唑并[1,5-A]嘧啶 [(2S,5R)-5-(4-氨基-1H-吡唑并[3,4-d]嘧啶-1-基)四氢呋喃-2-基]甲醇 VEGFR2激酶抑制剂IV N5-(6-氨基己基)-N7-苄基-3-异丙基吡唑并[1,5-a]嘧啶-5,7-二胺 N5-(1-环庚基-1H-吡唑并[3,4-d]嘧啶-6-基)吡啶-2,5-二胺 N3-(4-氟苯基)-1H-吡唑并[3,4-D]嘧啶-3,4-二胺 N-苄基-6-氯-1H-吡唑并[3,4-d]嘧啶-4-胺 N-苄基-1H-吡唑并[3,4-d]嘧啶-4-胺 N-甲基-1H-吡唑并[3,4-d]嘧啶-4-胺 N-[2-(3-氨基-3-氧代丙氧基)乙基]-6-(4-溴苄基)吡唑并[1,5-a]嘧啶-3-甲酰胺